SITC seeks nominations for the Steven A. Rosenberg Scholars Award

Immunotherapy before and after lung cancer surgery reduces death risk, disease recurrence

People with operable non-small cell lung cancers may fare better over the next few years by receiving immunotherapy treatments before and after surgery instead of only before surgery, according to an analysis by Johns Hopkins Kimmel Cancer Center investigators.

September 13, 2024

Vol.50 No.34

Drugs & Targets

FDA approves Tecentriq Hybreza for subcutaneous PD-(L)1 cancer immunotherapy

FDA approved Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs), the first and only PD-(L)1 inhibitor for subcutaneous injection.

September 13, 2024

Vol.50 No.34

Clinical Roundup

UTSW study reveals widespread disparities in immunotherapy use for patients with advanced kidney and bladder cancers

A study led by researchers at UT Southwestern Medical Center reveals significant disparities across the country in the use of immunotherapy for patients with advanced kidney and bladder cancers.

September 06, 2024

Vol.50 No.33

Clinical Roundup

Sarclisa combination improves PFS in newly diagnosed MM in phase III trial

Data from the IMROZ phase III trial demonstrated Sarclisa (isatuximab), in combination with standard-of-care bortezomib, lenalidomide, and dexamethasone (VRd) followed by Sarclisa-Rd (the IMROZ regimen), significantly reduced the risk of disease progression or death by 40%, compared to VRd followed by Rd in patients with newly-diagnosed multiple myeloma not eligible for transplant.

August 09, 2024

Vol.50 No.32

Clinical Roundup

Distinct pattern in protein production can predict severe side effects from skin cancer treatment

An activity pattern in certain genes responsible for building proteins known as spleen tyrosine kinases can predict which melanoma patients are likely to have severe side effects from immunotherapy designed to treat the most deadly skin cancer, a study shows.

August 09, 2024

Vol.50 No.32

Drugs & Targets

FDA approves Lymphir immunotherapy for r/r CTCL

FDA has approved Lymphir (denileukin diftitox-cxdl), a novel immunotherapy for the treatment of r/r cutaneous T-cell lymphoma after at least one prior systemic therapy.

August 09, 2024

Vol.50 No.32

SITC seeks nominations for the Steven A. Rosenberg Scholars Award

YOU MAY BE INTERESTED IN

Immunotherapy before and after lung cancer surgery reduces death risk, disease recurrence

FDA approves Tecentriq Hybreza for subcutaneous PD-(L)1 cancer immunotherapy

UTSW study reveals widespread disparities in immunotherapy use for patients with advanced kidney and bladder cancers

Sarclisa combination improves PFS in newly diagnosed MM in phase III trial

Distinct pattern in protein production can predict severe side effects from skin cancer treatment

FDA approves Lymphir immunotherapy for r/r CTCL

Renew today!

Subscriber content

Can you spare 10 minutes to complete a survey?

Login